Biobanking and Immunologic Monitoring

生物样本库和免疫监测

• 批准号: 10698160
• 负责人: JEROME RITZ
• 金额: $ 27.51万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-15 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10698160
• 关键词: Adult; Allogenic; Antigen Targeting; Biological Assay; Bone Marrow; Boston; Bronchoalveolar Lavage; Cells; Characteristics; Chronic; Clinical; Clinical Trials; Collection; Correlative Study; Cryopreservation; Cytomegalovirus; Cytometry; DNA; Dana-Farber Cancer Institute; Data; Disease; Dose; Enrollment; Enzyme-Linked Immunosorbent Assay; Equipment and supply inventories; Equity; Flow Cytometry; Fluorochrome; Hematopoietic Stem Cell Transplantation; Hospitals; Human Herpesvirus 4; Immunity; Immunologic Monitoring; Individual; Informed Consent; Institutional Review Boards; Interleukin-2; Intervention; Kinetics; Laboratories; Lymphocyte; Measures; Metals; Monitor; Monoclonal Antibodies; Mononuclear; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hospitals; Peripheral Blood Mononuclear Cell; Peripheral Stem Cell Transplantation; Phenotype; Plasma; Play; Policies; Population; Principal Investigator; Process; Protocols documentation; RNA; Research Personnel; Resources; Role; Sampling; Serum; Stem cell transplant; T cell reconstitution; Therapeutic Agents; Tissue Banks; Transplantation; Woman; Writing; antibody conjugate; biobank; chronic graft versus host disease; computerized; cytokine; donor stem cell; enzyme linked immunospot assay; experimental study; immune function; immune reconstitution; immunological intervention; improved; novel therapeutics; participant enrollment; patient privacy; pediatric patients; peripheral blood; prevent; programs; prospective; research study; sample collection; transplant database

Core 2 Project Summary/Abstract The purpose of this core is to provide a centralized laboratory resource for obtaining, cryopreserving and distributing patient samples and to monitor the kinetics of immune reconstitution following allogeneic hematopoietic stem cell transplantation (HCT) and following immune interventions to prevent or treat chronic GVHD. Prior to transplantation, peripheral blood mononuclear cells (PBMC), bone marrow and serum or plasma are obtained from all patients enrolled on clinical trials supported by this Program Project. PBMC, plasma and serum are also obtained from patients undergoing routine allogenic stem cell transplantation and normal stem cell donors for these individuals. Following HCT, peripheral blood, plasma and DNA samples are obtained at regular intervals. All of these samples are processed, cryopreserved, entered into a computerized inventory and made available to all of the investigators in this program. The HCT tissue bank inventory also has a very large number of serial samples from patients who have previously undergone allogeneic HCT at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Boston Children’s Hospital. Clinical outcome data on these patients is available in our HCT database. This inventory of annotated samples is also available to Program investigators. Finally, the tissue bank inventory includes serial samples obtained from previous clinical trials evaluating low dose IL-2 and other novel therapeutic agents in patients with chronic graft versus host disease (cGVHD). All banked samples have been collected from patients who have provided informed consent for sample collection for research studies. To monitor immune reconstitution after allogeneic HCT as well as interventions to prevent or treat GVHD, this core utilizes multi-parameter flow cytometry with a panel of fluorochrome- conjugated monoclonal antibodies or mass cytometry with panels of metal-conjugated antibodies. If needed, plasma concentrations of cytokines known to play important roles in immune reconstitution are measured by ELISA or panels of cytokines can be measured by Luminex. Reconstitution of T cell immunity to specific target antigens such as CMV and EBV is determined by ELISPOT and HLA-tetramers. Results of each of these assays are correlated with other parameters of immune function as well as with clinical outcomes.

核心2项目摘要/摘要 该核心的目的是提供一个集中的实验室资源，用于获取、冷冻保存和 分配患者样品并监测同种异体移植后免疫重建的动力学 造血干细胞移植（HCT）和随后的免疫干预，以预防或治疗慢性 GVHD。移植前，外周血单核细胞（PBMC）、骨髓和血清或血浆 从本计划项目支持的临床试验中招募的所有患者中获得。PBMC、血浆和 血清也得自进行常规同种异体干细胞移植和正常干细胞移植的患者。 这些人的细胞捐赠者在HCT之后，外周血、血浆和DNA样品在24小时获得。 有规律的间隔。所有这些样本都经过处理、冷冻保存，输入计算机化库存， 提供给这个项目的所有研究人员。HCT组织库库存也非常大， 来自既往在Dana-Farber接受过同种异体HCT的患者的系列样本数量 癌症研究所、布里格姆妇女医院和波士顿儿童医院。临床结局数据 患者在我们的HCT数据库中可用。该注释样本清单也可用于Program investigators.最后，组织库库存包括从之前的临床试验中获得的系列样本 评价低剂量IL-2和其他新型治疗药物在慢性移植物抗宿主病患者中的应用 （cGVHD）。所有库存样本均采集自提供样本知情同意书的患者 收集研究资料。监测同种异体HCT后的免疫重建以及干预措施 为了预防或治疗GVHD，该核心利用多参数流式细胞术和一组荧光染料， 偶联的单克隆抗体或具有金属偶联抗体组的质谱细胞术。如果需要的话， 已知在免疫重建中起重要作用的细胞因子的血浆浓度是通过 ELISA或细胞因子组可以通过Luminex测量。针对特异性靶标的T细胞免疫的重建 通过ELISPOT和HLA-四聚体测定抗原如CMV和EBV。每项试验的结果 与免疫功能的其他参数以及临床结果相关。